IO BIOTECH INC (IOBT) Stock Price, Forecast & Analysis
USA - NASDAQ:IOBT - US4497781090 - Common Stock
IOBT Key Statistics, Chart & Performance
The current stock price of IOBT is 0.8276 USD. In the past month the price increased by 26.68%. In the past year, price increased by 1.22%.
IOBT Latest News, Press Relases and Analysis
IOBT Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.59 | 410.48B | ||
| AMGN | AMGEN INC | 15.4 | 181.29B | ||
| GILD | GILEAD SCIENCES INC | 15.26 | 155.13B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.18 | 112.08B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.41 | 73.50B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 880.71 | 58.88B | ||
| INSM | INSMED INC | N/A | 40.84B | ||
| NTRA | NATERA INC | N/A | 28.04B | ||
| BIIB | BIOGEN INC | 10.01 | 24.56B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.67 | 21.10B | ||
| INCY | INCYTE CORP | 16.22 | 20.34B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 34.66 | 14.37B |
Related stock screener links
About IOBT
Company Profile
IO Biotech, Inc. engages in the development of immune modulating cancer therapies based on its T-win technology platform. The Company’s product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression. IO Biotech’s lead product candidate, IO102-IO103, is designed to target the immunosuppressive mechanisms mediated by key immunosuppressive proteins such as IDO and PD-L1. The firm develops a pipeline of product candidates that leverage its T-win technology platform to address targets within the TME. The firm is spin-off of National Cancer for Center Immune Therapy at Herlev University Hospital in Denmark.
Company Info
IO BIOTECH INC
Ole Maaloes Veh 3
COPENHAGEN DK
Employees: 80
Phone: 4570702980
IO BIOTECH INC / IOBT FAQ
What does IO BIOTECH INC do?
IO Biotech, Inc. engages in the development of immune modulating cancer therapies based on its T-win technology platform. The Company’s product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression. IO Biotech’s lead product candidate, IO102-IO103, is designed to target the immunosuppressive mechanisms mediated by key immunosuppressive proteins such as IDO and PD-L1. The firm develops a pipeline of product candidates that leverage its T-win technology platform to address targets within the TME. The firm is spin-off of National Cancer for Center Immune Therapy at Herlev University Hospital in Denmark.
What is the current price of IOBT stock?
The current stock price of IOBT is 0.8276 USD. The price increased by 1.71% in the last trading session.
Does IOBT stock pay dividends?
IOBT does not pay a dividend.
How is the ChartMill rating for IO BIOTECH INC?
IOBT has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Which stock exchange lists IOBT stock?
IOBT stock is listed on the Nasdaq exchange.
Can you provide the PE ratio for IOBT stock?
IO BIOTECH INC (IOBT) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.53).
Can you provide the number of employees for IO BIOTECH INC?
IO BIOTECH INC (IOBT) currently has 80 employees.
IOBT Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to IOBT. When comparing the yearly performance of all stocks, IOBT is a bad performer in the overall market: 90.15% of all stocks are doing better.
IOBT Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to IOBT. IOBT has a bad profitability rating. Also its financial health evaluation is rather negative.
IOBT Financial Highlights
Over the last trailing twelve months IOBT reported a non-GAAP Earnings per Share(EPS) of -1.53. The EPS decreased by -6.25% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -245.68% | ||
| ROE | -6531.78% | ||
| Debt/Equity | 4.22 |
IOBT Forecast & Estimates
12 analysts have analysed IOBT and the average price target is 2.51 USD. This implies a price increase of 203.6% is expected in the next year compared to the current price of 0.8276.